Takeda Highlights China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
In: Wireless News, 2024-01-10
Zeitungsartikel
Zugriff:
Titel: |
Takeda Highlights China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
|
---|---|
Zeitschrift: | Wireless News, 2024-01-10 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|